Phase I Trial of Tubulin Inhibitor 1069C85
Author Information
Author(s): I Judson, E Briasoulis, F Raynaud, J Hanwell, C Berry, H Lacey
Primary Institution: Cancer Research Campaign Centre for Cancer Therapeutics, The Institute of Cancer Research
Hypothesis
The tubulin-binding agent 1069C85 was developed to overcome multidrug resistance associated with existing anti-tubulin agents.
Conclusion
The study concluded that the unpredictable toxicity of 1069C85 made it incompatible with safe evaluation in further clinical trials.
Supporting Evidence
- The study involved 39 patients treated with varying doses of 1069C85.
- Severe central neurotoxicity was observed in some patients, leading to the trial's closure.
- The formulation of the drug was found to be inconsistent, affecting its absorption.
- Patients had a median age of 53 years, with a range from 26 to 73 years.
- Most patients had received multiple previous chemotherapy regimens.
Takeaway
Researchers tested a new cancer drug called 1069C85 to see if it could help patients whose cancer didn't respond to other treatments, but it caused serious side effects.
Methodology
A phase I study was performed using a single oral dose every 3 weeks, with dose escalation based on pharmacokinetics.
Limitations
The formulation proved to be unsatisfactory, resulting in inconsistent absorption and unpredictable toxicity.
Participant Demographics
{"age":{"median":53,"range":"26-73"},"sex":{"female":29,"male":10},"performance_status":{"0":5,"1":27,"2":7},"tumour_types":{"ovary":16,"breast":5,"sarcoma":4,"lung":3,"colorectal":3,"melanoma":2,"unknown_primary":2,"mesothelioma":2,"stomach":1,"tonsil":1},"previous_chemotherapy_regimens":{"1-2":23,">3":16},"courses_of_1069C85":{"mean":2.4,"range":"1-12"}}
Want to read the original?
Access the complete publication on the publisher's website